Summit boosts Instil, BioNTech as lead drug beats Merck's Keytruda [Seeking Alpha]
Instil Bio, Inc. (TIL)
NASDAQ:AMEX Investor Relations:
nasdaq.com/symbol/til
Company Research
Source: Seeking Alpha
anti-PD-1 therapy Keytruda in a late-stage trial, Instil Bio ( NASDAQ: TIL ) and BioNTech ( NASDAQ: BNTX ), which develop similar drugs, have recorded sharp gains. Shares of Summit ( SMMT ) spiked after it announced on Sunday that lung cancer patients who received ivonescimab, a PD-1/VEGF bispecific antibody developed with its Chinese partner Akeso ( OTCPK:AKESF ) lived more than five months on average compared to those who were on Keytruda. The Miami, Florida-based biotech has raised $235M in gross proceeds since the announcement, as investors focused on ivonescimab's drug class, designed to treat cancer via a dual action on tumor-associated molecules, PD-1 and VEGF. Biotechs with similar pipeline assets rallied in reaction, with Instil Bio ( TIL ) and BioNTech ( BNTX ) among notable gainers. On Friday, Baird raised its price target on Instil Bio ( TIL ) to $180 from $32 per share, citing more encouraging data for the drug class at the European Society for Molecular Oncology
Show less
Read more
Impact Snapshot
Event Time:
TIL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TIL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TIL alerts
High impacting Instil Bio, Inc. news events
Weekly update
A roundup of the hottest topics
TIL
News
- BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock Up [Yahoo! Finance]Yahoo! Finance
- Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire
- Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast CancerGlobeNewswire
- Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher? [Yahoo! Finance]Yahoo! Finance
- Futures Gain As Expectations For A 50bps Rate Cut Spike [zero hedge]zero hedge
TIL
Earnings
- 11/13/24 - Miss
TIL
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/13/24 - Form S-3
- TIL's page on the SEC website